Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Relocates to New Waltham Space; Additional Hires Planned

NEW YORK, May 20 (GenomeWeb News) - Following on its name change from Beyond Genomics earlier this year, BG Medicine has relocated its headquarters to a larger facility in Waltham, Mass., the company said yesterday.


BG Medicine is now located "a couple of miles up the road" from their original space, according to Pieter Muntendam, the company's president. The new space is around 20,000 square feet compared with roughly 12,000 square feet in the older office.


Muntendam told GenomeWeb News that the new space is "better laid out" and will "accommodate the [company's] growth better than the other" facility. He said the company expects to hire additional staffers to fill out the additional space. He said the growth will be "both [in] wet lab scientists and computational ... groups that interpret the data." He could not elaborate. BG Medicine currently employs 40 people.


As GenomeWeb News reported in February, BG Medicine plans to pursue the drug-development applications of its systems pharmacology platform. As part of the realignment, the company appointed Muntendam as its new president. Muntendam most recently led the Biopharmaceutical and Healthcare division of NetNumina, an informatics services company, the statement added.


According to BG, its systems pharmacology platform integrates metabolite, protein, and gene transcript profiling to "characterize the molecular changes due to disease or drug effects." The company's goal will be to "improve upon leading drug classes, identify new indications, and explore novel drug combinations," Muntendam said.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.